Neuroprotectants offer hope to glaucoma sufferers

Article

Erythropoietin (EPO), ciliary neurotrophic factor (CNTF), and wolfberry seem to provide neuroprotection of retinal ganglion cells in a rat model of ocular hypertension.

Erythropoietin (EPO), ciliary neurotrophic factor (CNTF), and wolfberry seem to provide neuroprotection of retinal ganglion cells in a rat model of ocular hypertension, according to Kwoh-fai So, PhD, chairman of the Department of Anatomy, University of Hong Kong.

Dr So and colleagues created a rat model of ocular hypertension in which the retinal ganglion cells were affected, and tested EPO, CNTF, and wolfberry, a Chinese herb, in three separate experiments. All three seemed to be neuroprotective of the retinal ganglion cells.

“Endogenous EPO seems to have a recovery mechanism after retinal injury and the retinal ganglion cells might be rescued by endogenous EPO,” Dr So said. “CNTF enhanced regeneration and is an effective neurotrophic factor in protecting retinal ganglion cells in the rat model.

“Wolfberry is very interesting to us because it improves visual acuity, benefits the liver and kidney, and adjusts the body’s immunity and also was protective of retinal ganglion cells in this rat model,” Dr So said. “Wolfberry might be a useful treatment because it is a safe herbal medicine that has been used for a long time.”

Investigators are also studying the effect of wolfberry on microglia.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.